

Q2

**2019
RESULTS**

**OLIVIER
BRANDICOURT**
CHIEF EXECUTIVE
OFFICER, SANOFI



“Sanofi continued its growth phase with a solid business performance in the second quarter, driven by Sanofi Genzyme, Sanofi Pasteur and Emerging Markets”

**COMPANY
SALES
& BUSINESS
EPS***

Q2 2019 SALES*

€8,628M
+3.9% (+5.5%)

Q2 2019 BUSINESS EPS*

€1.31
+4.8% (+4.8%)

*Growth rates are expressed at constant exchange rates (CER). Growth rate in parentheses are expressed on a reported basis.

€2,292M



Sanofi Genzyme
(Specialty Care)

€2,281M



Primary Care

€1,891M



China & Emerging
Markets

€1,143M



Consumer
Healthcare

€1,021M



Sanofi Pasteur
(vaccines)

**SALES
BY GLOBAL
BUSINESS
UNIT**

**SALES
BY GEOGRAPHY**

*Eurasia :
Russia, Ukraine, Georgia,
Belarus, Armenia and
Turkey

**Rest of the World :
Japan, South Korea,
Canada, Australia, New
Zealand and Puerto Rico.

- 1 U.S €2,851M
 - 2 EUROPE €2,164M
 - 3 LATIN AMERICA €690M
 - 4 EURASIA* €322M
 - 5 ASIA €1,132M
 - 6 AFRICA & MIDDLE EAST €553M
- ROW** €889M

FOR FURTHER INFORMATION ON Q2 2019 RESULTS AND DEFINITIONS OF FINANCIAL INDICATORS, PLEASE REFER TO THE PRESS RELEASE ISSUED ON JULY 29, 2019 AT:

[HTTPS://WWW.SANOFI.COM/EN/INVESTORS](https://www.sanofi.com/en/investors)

SANOFI.COM



@Sanofi



Sanofi



@Sanofi

SANOFI.US



@SanofiUS



SanofiUS